Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial–mesenchymal transition phenotype

(2018) Jing Xu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer

(2017) Hao Bai et al.   OncoTargets and Therapy

Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors

(2017) Junko Hamamoto et al.   Oncology Letters

Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing

(2017) Mi-Young Park et al.   Oncotarget

Incidence and mortality of lung cancer: global trends and association with socioeconomic status

(2017) Martin C. S. Wong et al.   Scientific Reports

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations

(2017) Bin Zou et al.   Scientific Reports

Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors

(2016) Rajendar K. Mittapalli et al.   CANCER RESEARCH

Characterization of passive permeability at the blood–tumor barrier in five preclinical models of brain metastases of breast cancer

(2016) Chris E. Adkins et al.   CLINICAL & EXPERIMENTAL METASTASIS

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

(2016) P. Ballard et al.   CLINICAL CANCER RESEARCH

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

(2016) Shuhang Wang et al.   Journal of Hematology & Oncology

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line

(2016) Zheng-Hai Tang et al.   Oncotarget

Control of the blood-brain barrier function in cancer cell metastasis

(2015) Kinga G. Blecharz et al.   BIOLOGY OF THE CELL

Emerging Strategies for Treating Brain Metastases from Breast Cancer

(2015) David P. Kodack et al.   CANCER CELL

Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

(2015) Christina S. Baik et al.   Journal of Thoracic Oncology

The Blood–Brain Barrier

(2015) Richard Daneman et al.   Cold Spring Harbor Perspectives in Biology

Ultrasonography-Guided Intracardiac Injection

(2013) Lukxmi Balathasan et al.   AMERICAN JOURNAL OF PATHOLOGY

Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases

(2013) A. Ali et al.   Current Oncology

Role of the Blood-Brain Barrier in the Formation of Brain Metastases

(2013) Imola Wilhelm et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

(2013) Yan Chen et al.   LUNG CANCER

P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model

(2013) Chris E. Adkins et al.   Frontiers in Pharmacology

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor

(2011) Britta Weber et al.   Journal of Thoracic Oncology

Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

(2010) P. R. Lockman et al.   CLINICAL CANCER RESEARCH

Treatment of Brain Metastasis from Lung Cancer

(2010) Alexander Chi et al.   Cancers